Healthcare - Medical - Pharmaceuticals - NASDAQ - US
$ 0.0081
8 %
$ 5.57 M
Market Cap
None
P/E
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.[ Read More ]
The intrinsic value of one ATNFW stock under the base case scenario is HIDDEN Compared to the current market price of 0.0081 USD, CannBioRx Life Sciences Corp. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ATNFW
FINANCIALS
0
REVENUE
-13.5 M
OPERATING INCOME
-19.9 M
NET INCOME
-10.9 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
5.91 M
FINANCING CASH FLOW
0
REVENUE
-979 K
OPERATING INCOME
-837 K
NET INCOME
-224 K
OPERATING CASH FLOW
0
INVESTING CASH FLOW
-476 K
FINANCING CASH FLOW
Balance Sheet Decomposition
CannBioRx Life Sciences Corp.
| Current Assets | 3.64 M |
| Cash & Short-Term Investments | 1.98 M |
| Receivables | 0 |
| Other Current Assets | 1.66 M |
| Non-Current Assets | 1.62 M |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 1.62 M |
| Current Liabilities | 5.06 M |
| Accounts Payable | 2.16 M |
| Short-Term Debt | 1.03 M |
| Other Current Liabilities | 1.87 M |
| Non-Current Liabilities | 325 K |
| Long-Term Debt | 19.9 K |
| Other Non-Current Liabilities | 305 K |
EFFICIENCY
Earnings Waterfall
CannBioRx Life Sciences Corp.
| Revenue | 0 |
| Cost Of Revenue | 106 K |
| Gross Profit | -106 K |
| Operating Expenses | 13.4 M |
| Operating Income | -13.5 M |
| Other Expenses | 6.46 M |
| Net Income | -19.9 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
15606.86%
ROE
-379.03%
ROA
153390000.83%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CannBioRx Life Sciences Corp.
| Net Income | -19.9 M |
| Depreciation & Amortization | 106 K |
| Capital Expenditures | 3 |
| Stock-Based Compensation | 2.28 M |
| Change in Working Capital | -14.1 K |
| Others | 8.69 M |
| Free Cash Flow | -10.9 M |
Wall Street Analysts Price Targets
CannBioRx Life Sciences Corp.
ATNFW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
CannBioRx Life Sciences Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
4.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
4.7 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
11 months ago
Dec 15, 2023
|
Sell 4.7 K USD
|
Feldmann Marc
Director |
- 25000
|
0.188 USD |
|
11 months ago
Dec 15, 2023
|
Bought 4.7 K USD
|
Woody James N.
Chief Executive Officer |
+ 25000
|
0.188 USD |
|
1 year ago
Jun 01, 2023
|
Bought 22.1 K USD
|
STEINMAN LAWRENCE
Director |
+ 18000
|
1.226 USD |
|
1 year ago
May 31, 2023
|
Bought 11.5 K USD
|
McGovern Jr. Donald A.
Director |
+ 10000
|
1.147 USD |
|
1 year ago
May 19, 2023
|
Bought 5.8 K USD
|
McGovern Jr. Donald A.
Director |
+ 5000
|
1.16 USD |
|
1 year ago
May 18, 2023
|
Bought 10.5 K USD
|
McGovern Jr. Donald A.
Director |
+ 10000
|
1.05 USD |
|
1 year ago
May 18, 2023
|
Bought 7.51 K USD
|
Marrone Pamela G
Director |
+ 7082.019
|
1.06 USD |
|
1 year ago
May 18, 2023
|
Bought 5.21 K USD
|
Pamir Ozan
CFO |
+ 5162.077
|
1.01 USD |
|
1 year ago
May 18, 2023
|
Bought 41.2 K USD
|
Woody James N.
Chief Executive Officer |
+ 40000
|
1.03 USD |
7. News
8. Profile Summary
CannBioRx Life Sciences Corp. ATNFW
COUNTRY
US
INDUSTRY
Medical - Pharmaceuticals
MARKET CAP
$ 5.57 M
Dividend Yield
0.00%
Description
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Contact
Building 4, Palo Alto, 94306
http://www.180lifesciences.com
IPO Date
None
Employees
4
Officers
Prof. Jagdeep Nanchahal M.D., Ph.D.
Co-Founder & Chairman of Clinical Advisory Board
Mr. Jason Assad
Director of IR
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder & Director
Sir Marc Feldmann Ph.D.
Co-Founder